TY  - JOUR
AU  - Jančić, Ivan
AU  - Arsenović-Ranin, Nevena
AU  - Sefik-Bukilica, Mirjana
AU  - Živojinović, Slađana
AU  - Damjanov, Nemanja
AU  - Spasovski, Vesna
AU  - Srzentić, Sanja
AU  - Stanković, Biljana
AU  - Pavlović, Sonja
PY  - 2013
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/1998
AB  - To examine whether -174G/C interleukin-6 (IL-6) gene polymorphism, previously reported to correlate with IL-6 level, influences response to etanercept therapy in patients with rheumatoid arthritis. Seventy-seven patients with active RA were studied, at baseline and 6- and 12-month follow-up after etanercept therapy. Treatment response was estimated according to the European League Against Rheumatism response criteria. RA patients were genotyped for -174G/C IL-6 gene polymorphism by the PCR-RFLP method, and influence of genotype at this polymorphism to clinical response to etanercept was assessed. After 12 months of treatment, the percentage of responders (patients who had DAS28 improvement > 1.2) was significantly increased in patients carrying the IL-6 -174G/G genotype (95.7 %) compared with those with the G/C (75.6 %) or CC (44.4 %) genotype (p = 0.006 by Chi-square test). No significant difference in the mean values of DAS28 improvement was observed between groups with different genotype. RA patients with an IL-6 -174GG genotype respond to etanercept better than patients with GC or CC genotype. This finding, if confirmed in future studies, suggests that the -174G/C IL-6 polymorphism may be a genetic marker of responsiveness to tumor necrosis factor-alpha (TNF-alpha) blockers in RA.
PB  - Springer Heidelberg, Heidelberg
T2  - Rheumatology International
T1  - -174G/C interleukin-6 gene promoter polymorphism predicts therapeutic response to etanercept in rheumatoid arthritis
VL  - 33
IS  - 6
SP  - 1481
EP  - 1486
DO  - 10.1007/s00296-012-2586-y
ER  - 

@article{
author = "Jančić, Ivan and Arsenović-Ranin, Nevena and Sefik-Bukilica, Mirjana and Živojinović, Slađana and Damjanov, Nemanja and Spasovski, Vesna and Srzentić, Sanja and Stanković, Biljana and Pavlović, Sonja",
year = "2013",
abstract = "To examine whether -174G/C interleukin-6 (IL-6) gene polymorphism, previously reported to correlate with IL-6 level, influences response to etanercept therapy in patients with rheumatoid arthritis. Seventy-seven patients with active RA were studied, at baseline and 6- and 12-month follow-up after etanercept therapy. Treatment response was estimated according to the European League Against Rheumatism response criteria. RA patients were genotyped for -174G/C IL-6 gene polymorphism by the PCR-RFLP method, and influence of genotype at this polymorphism to clinical response to etanercept was assessed. After 12 months of treatment, the percentage of responders (patients who had DAS28 improvement > 1.2) was significantly increased in patients carrying the IL-6 -174G/G genotype (95.7 %) compared with those with the G/C (75.6 %) or CC (44.4 %) genotype (p = 0.006 by Chi-square test). No significant difference in the mean values of DAS28 improvement was observed between groups with different genotype. RA patients with an IL-6 -174GG genotype respond to etanercept better than patients with GC or CC genotype. This finding, if confirmed in future studies, suggests that the -174G/C IL-6 polymorphism may be a genetic marker of responsiveness to tumor necrosis factor-alpha (TNF-alpha) blockers in RA.",
publisher = "Springer Heidelberg, Heidelberg",
journal = "Rheumatology International",
title = "-174G/C interleukin-6 gene promoter polymorphism predicts therapeutic response to etanercept in rheumatoid arthritis",
volume = "33",
number = "6",
pages = "1481-1486",
doi = "10.1007/s00296-012-2586-y"
}

Jančić, I., Arsenović-Ranin, N., Sefik-Bukilica, M., Živojinović, S., Damjanov, N., Spasovski, V., Srzentić, S., Stanković, B.,& Pavlović, S.. (2013). -174G/C interleukin-6 gene promoter polymorphism predicts therapeutic response to etanercept in rheumatoid arthritis. in Rheumatology International
Springer Heidelberg, Heidelberg., 33(6), 1481-1486.
https://doi.org/10.1007/s00296-012-2586-y

Jančić I, Arsenović-Ranin N, Sefik-Bukilica M, Živojinović S, Damjanov N, Spasovski V, Srzentić S, Stanković B, Pavlović S. -174G/C interleukin-6 gene promoter polymorphism predicts therapeutic response to etanercept in rheumatoid arthritis. in Rheumatology International. 2013;33(6):1481-1486.
doi:10.1007/s00296-012-2586-y .

Jančić, Ivan, Arsenović-Ranin, Nevena, Sefik-Bukilica, Mirjana, Živojinović, Slađana, Damjanov, Nemanja, Spasovski, Vesna, Srzentić, Sanja, Stanković, Biljana, Pavlović, Sonja, "-174G/C interleukin-6 gene promoter polymorphism predicts therapeutic response to etanercept in rheumatoid arthritis" in Rheumatology International, 33, no. 6 (2013):1481-1486,
https://doi.org/10.1007/s00296-012-2586-y . .